Global Regulatory Landscape for Fermentation Strains: A Strategic Analysis of EFSA QPS, FDA GRAS, and East Asian Frameworks

1. Introduction: The Taxonomic Logic of Strain Regulation

In cross-border trade, "fermentation strains" are not regulated as a monolithic entity. They are categorized based on the nature of the finished product and functional positioning:

● Live Probiotics/Starters: Products containing viable microorganisms for direct consumption, focusing on safety, stability, and efficacy claims.

● Traditional Ferments: Emphasis on historical consumption and contaminant control; the strain itself usually does not require separate approval.

● Production Microorganisms: Strains used to manufacture enzymes, amino acids, vitamins, and HMOs. The finished product is typically a metabolite free of viable cells. This category faces the most stringent safety assessments, focusing on the biosafety of the production strain and the downstream purification to control host cell residuals (DNA/proteins).

2. European Union: The QPS-Centric Risk Assessment System

The European Food Safety Authority (EFSA) has established the unique Qualified Presumption of Safety (QPS) system, which serves as the cornerstone for all microbial introductions.

• Taxonomic Threshold: QPS evaluation is based on taxonomic identity, typically at the genus or species level. Only strains belonging to a QPS-listed taxon can benefit from a streamlined Novel Food or additive application process.

• Qualifications: QPS status is not unconditional. EFSA imposes "qualifications" on specific strains, such as "absence of bacteriocin production," "non-toxigenic," or "for production purposes only." For instance, Bacillus sonorensis, added in the 2026 opinion, carries strict conditions for production use.

• Production Strains Specificity: For microorganisms producing enzymes or additives, QPS status can waive certain toxicological data. Non-QPS or Genetically Modified Microorganisms (GMMOs) require comprehensive dossiers, including Whole Genome Sequencing (WGS) data, analysis of mobile genetic elements, and verification of viable cell/DNA residuals in the final product.

• Compliance Imperative: Exporters must provide a Culture Collection Deposit (Budapest Treaty), WGS data, and a QPS status mapping document.

3. United States: The Dual-Track GRAS and NDI System and Increasing Scrutiny

The US FDA does not have a standalone "probiotic" category. Oversight occurs via the GRAS (Generally Recognized As Safe) and NDI (New Dietary Ingredient) pathways.

• GRAS Pathway: Applicable to foods and beverages. Companies may perform a self-affirmation or submit a GRAS Notification (GRN) to the FDA. Given the 2026 regulatory trend proposing to shift GRAS from "voluntary" to "mandatory" notification, exporters should prepare dossiers to submission standards (including expert panel consensus, toxicological reviews, and dietary exposure assessments).

• NDI Pathway: Applicable to dietary supplements. If a strain was not marketed in the US before October 15, 1994, an NDI notification is mandatory.

• Production Strains: For fermentation-derived enzymes, amino acids, or vitamins, the FDA focuses on the safety of the host strain, the purity of the fermentation process, and the capability of downstream processing to remove impurities. Data on Host Cell Protein (HCP) and residual DNA clearance rates are essential.

• Compliance Imperative: Labels must declare the end-of-shelf-life CFU count, and disease treatment claims are strictly prohibited.

4. Japan: Dual Health Claim System Based on History of Consumption

Japan’s Ministry of Health, Labour and Welfare (MHLW) and Consumer Affairs Agency (CAA) maintain a rigorous strain oversight system.

• Traditional Foods & Additives: Traditional fermentation strains (e.g., Sake yeast, Bacillus subtilis var. natto) are managed as general foods. Novel strains require safety assessments.

• Health Claim Systems: 

• FOSHU (Foods for Specified Health Uses): Requires stringent human clinical trials and government approval for high-intensity function claims.

• FFC (Foods with Function Claims): Operates on a notification basis, requiring only scientific substantiation. This is currently the mainstream channel for probiotic products, though CAA scrutiny on genotypic identification, CFU stability, and evidence quality is intensifying.

Non-Milk Probiotics Regulation: Dairy products (powder or liquid) containing non-milk probiotics require additional submissions regarding facility information, strain safety dossiers, and risk assessments for D-lactic acid/secondary bile acids.

Compliance Imperative: Provision of genotypic identification reports and compliance documents aligned with Japan’s JAMP standards is mandatory.

5. Korea: MFDS Tiered Management of Health Functional Foods (HFF)

The Korean MFDS employs a dual-track system of "Notified" and "Individually Recognized" ingredients for probiotics.

• Notified Ingredients: Strains with pre-established standards, dosages, and functions announced by MFDS (e.g., certain Lactobacillus strains) can be used directly without further approval.

• Individually Recognized Ingredients: Novel strains or new functions (e.g., immune modulation, metabolic improvement) require submission of comprehensive data, including WGS, antimicrobial resistance, hemolysis, cytotoxicity, and human intervention trials, followed by MFDS approval.

• Production Strains: Microorganisms used for manufacturing amino acids or polysaccharides must comply with MFDS food additive specifications. Importers must complete facility registration and GMP audits.

• Compliance Imperative: Labels must clearly state the strain name, CFU count, and storage conditions. Health claims must be strictly confined to the "Health Functional Food" scope.

6. Compliance SOP and Documentation Matrix for Exporters

To ensure seamless cross-border trade, the following standardized workflow is recommended:

Conclusion:

Global compliance for fermentation strains is a systematic endeavor intersecting taxonomy, microbiology, toxicology, and regulatory affairs. Qingdao Natural Life, with its profound understanding of EFSA QPS, FDA GRAS, and East Asian regulatory frameworks, offers end-to-end solutions from strain screening and compliance assessment to documentation support.

Call to Action (CTA):

Need a tailored market access strategy for your fermentation strains in the EU, US, Japan, or South Korea? Contact the Qingdao Natural Life Regulatory Affairs team to obtain a customized compliance white paper and TDS templates.